source
- Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trialPfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…
- HHS unveils ARPA-H SURPASS program to accelerate clinical trial designOn Oct 1, 2026 the U.S. Department of Health and Human Services announced a new initiative under the Advanced Research Projects Agency for Health. The initiative, named the Simulation-augmented, R…